281 related articles for article (PubMed ID: 12552995)
1. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
[TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide specific antigen (TPS) as a tumor marker in nasopharyngeal carcinoma.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(6C):4661-3. PubMed ID: 11205197
[TBL] [Abstract][Full Text] [Related]
3. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
Lin WY; Yen TC; Cheng KY; Wang SJ
Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
[TBL] [Abstract][Full Text] [Related]
4. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
[TBL] [Abstract][Full Text] [Related]
5. Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
Lee JK; Tsai SC; Hsieh JF; Ho YJ; Sun SS; Kao CH
Anticancer Res; 2000; 20(6C):4765-8. PubMed ID: 11205215
[TBL] [Abstract][Full Text] [Related]
6. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
8. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
9. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
10. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
Tsai SC; Kao CH; Wang SJ
Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
[TBL] [Abstract][Full Text] [Related]
11. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
12. [A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
Ychou M; Khemissa-Akouz F; Kramar A; Senesse P; Grenier J
Bull Cancer; 2001 Oct; 88(10):1023-7. PubMed ID: 11713038
[TBL] [Abstract][Full Text] [Related]
13. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
[TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx.
Alkotyfan K; Wiegand S; Müller HH; Windfuhr JP; Werner JA; Sesterhenn AM
Anticancer Res; 2010 Jun; 30(6):2291-6. PubMed ID: 20651382
[TBL] [Abstract][Full Text] [Related]
16. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
Pavićević R; Milicić J; Bubanović G; Supe S
Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
[TBL] [Abstract][Full Text] [Related]
17. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G
Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC.
Molina R; Torres MD; Moragas M; Filella X; Jo J; Giménez N; Traserra J; Ballesta AM
Anticancer Res; 1995; 15(2):479-84. PubMed ID: 7763026
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
20. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]